TD Asset Management
AUTL

TD Asset Management’s Autolus Therapeutics AUTL Stock Holding History

TD Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-98,406
Closed -$357K – 1270
2024
Q3 		$357K Sell
98,406
-108,642
-52% -$433K ﹤0.01% 1329
2024
Q2 		$721K Sell
207,048
-135,358
-40% -$584K ﹤0.01% 1217
2024
Q1 		$2.18M Buy
342,406
+207,106
+153% +$1.29M ﹤0.01% 988
2023
Q4 		$871K Buy
+135,300
New +$516K ﹤0.01% 1203
2020
Q1 		– Sell
-17,057
Closed -$225K – 1370
2019
Q4 		$225K Sell
17,057
-3,072
-15% -$40.2K ﹤0.01% 1356
2019
Q3 		$250K Sell
20,129
-1,100
-5% -$14.5K ﹤0.01% 1278
2019
Q2 		$342K Buy
21,229
+10,680
+101% +$239K ﹤0.01% 1232
2019
Q1 		$332K Buy
10,549
+400
+4% +$11.4K ﹤0.01% 1246
2018
Q4 		$333K Buy
10,149
+200
+2% +$6.58K ﹤0.01% 1289
2018
Q3 		$300K Buy
9,949
+300
+3% +$8.1K ﹤0.01% 1368
2018
Q2 		$258K Buy
+9,649
New +$255K ﹤0.01% 1362

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

TD Asset Management's AUTL Position: Q4 2024 in Review

TD Asset Management sold out of Autolus Therapeutics (AUTL) in Q4 2024, closing a stake of 98,406 shares — an estimated $357K sold.

TD Asset Management first reported a position in AUTL in Q2 2018 and held it in 11 quarters. The position peaked at $2.18M in Q1 2024. 110 funds tracked by Wall St. Rank hold AUTL as of Q4 2024.

  • TD Asset Management reported no remaining Autolus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • TD Asset Management sold 98,406 Autolus Therapeutics shares in Q4 2024, an estimated $357K.
  • TD Asset Management first reported a position in Autolus Therapeutics in Q2 2018 and held it in 11 quarters.
  • TD Asset Management's Autolus Therapeutics position peaked at $2.18M in Q1 2024.
  • 110 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2024.

Based on TD Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.